Tillkännagivande • Mar 03

Omega Laboratories Inc and Cannabix Technologies Inc Publish Peer-Reviewed Validation Study Demonstrating Accuracy of Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies Breath Collection Unit

Omega Laboratories, Inc. and Cannabix Technologies Inc. announced the peer-reviewed publication of a study published by Oxford University Press in the Journal of Analytical Toxicology titled: "Simultaneous Analysis of ?9-THC, ?8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." The study demonstrates the accuracy and utility of Omega Laboratories' analytical method for detecting cannabinoids in breath samples collected using Cannabix Technologies' Breath Collection Unit and Breath Cartridges—further validating the system as the leading solution for identifying recent marijuana use. This breath-based testing system offers a reliable, non-invasive solution for detecting recent cannabis consumption. This capability fills a critical gap left by traditional methods, which often detect historical—rather than recent—use. In May of 2024 Omega and Cannabix entered a strategic partnership to accelerate design improvements on the Cannabix Breath Collection Unit as well as the laboratory test method. Over the course of 20 months, Cannabix made several key enhancements to the BCU while Omega refined the analytical methodology to test breath for usage of marijuana. These successful efforts were combined into the validation study recently published by the Journal of Analytical Toxicology. Detection of recent cannabis use in exhaled breath offers an alternative to the more invasive and intrusive testing methods using blood or urine. Breath testing, long established for alcohol detection, has recently gained attention for drug testing following evidence that multiple substances can be identified in breath after consumption. The detection window in breath correlates with those found in blood and can assist with the identification of recency of use within the last 4 hours prior to collection. Omega has refined precision testing at these low levels for decades by being experts in utilizing hair samples to detect long-term drug usage. Omega's laboratory validated method combined with the Cannabix Breath Collection Unit has created the most commercially viable, non-invasive system for identifying same-day THC usage. Publication in the Journal of Analytical Toxicology indicates the research on the identification and measurement of toxic substances in biological samples has passed rigorous peer review. The method was validated according to ANSI/ASB Standard 036, First Edition 2019 guidelines. Omega's method validation builds upon dozens of previously published papers while introducing several new key findings. These include: The ability to simultaneously quantify multiple cannabinoids via breath aerosols including ?9-tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), cannabidiol (CBD), and cannabinol (CBN). The validation of a robust laboratory method that is quicker and simpler than previous approaches while achieving improved detection sensitivity and precision. The establishment of breath sample stability for up to 7 days via the Cannabix Breath Collection Kit. Further confirmation that the concentration versus time trends for THC metabolism assessed from breath correlate with those previously reported from blood. Due to testing complexity requiring the use of LC-MS/MS, analysis must be performed in a laboratory. Collections performed at the roadside, workplace or in a clinic environment are sent to the laboratory and tested to see if a person had consumed marijuana 15 minutes to 4 hours prior to an incident. The breath collection process includes an ambient air sample followed by an A & B sample which are collected simultaneously with the use of the Cannabix collection cartridge. Omega screens the A sample using LC-MS/MS then, if presumptively positive, the B sample is also tested using LC-MS/MS. If both samples are positive the ambient air sample is tested to rule-out environmental contamination. Cannabix is currently working to ramp up manufacturing of the BCU's and Breath Collection Kits. The Cannabix BCU brings several advantages: Omega's validation helps establish the Cannabix BCU as a stable, consistent and portable tool for breath collection. The BCU offers a quick, non-invasive collection method regardless of subject's lung function. The BCU adds several safeguards to the reproducible collection process, including the monitoring of subject's breath pressure and volume, the ability to collect ambient air for specimen validity, and A & B cartridges for a dual testing process. The Breath Collection Kit cartridges used by the BCU are currently the most robust method of sending breath samples for laboratory testing. The sturdy nature of the cartridges combined with shipping stability time helps ensure that samples can be successfully processed once received at Omega Laboratories.

Tillkännagivande • Aug 26

Cannabix Technologies Inc. Correlates THC in Breath and Blood Using Proprietary Sample Collection and Analysis Hardware in Southern US Study

Cannabix Technologies Inc. continued to successfully test a supplemental version of its FAIMS technology for detection of 9-tetrahydrocannabinol and related analytes in human breath in new comprehensive multi-analysis study of subjects under the influence of marijuana in the southern United States. In the Southern US study, Cannabix is working alongside toxicologists and law enforcement officers who are testing subjects under the influence of marijuana. The Company’s technology (proprietary breath capture and marijuana detection equipment, described below) is being used side by side with several conventional drug screening methods (blood, oral fluid etc.). Further details of the study will be available in due course when disclosure approvals are granted to the Company. In June and July, Cannabix participated in two testing day events held in two different US cities. Early study data is demonstrating very consistent correlation of levels of THC between breath samples collected and analyzed with Cannabix hardware and the current standard of whole blood. The Company’s updated handheld Breath Collection Unit and newly developed laboratory “MS Breath Sampler” were used together to provide a new ground-breaking method for drug detection that complements gold-standard mass spectrometry (MS), and significantly simplifies laboratory analysis methods, reduces sample turnaround time thus minimizing operating costs, while maintaining sensitive, precise results. The Company has developed a unique breath capture system, capable of collecting low volatility analytes, such as THC, from approximately 5 breaths, which is the first time that such a capability for low volatility analytes has been developed. In addition, the Cannabix device captures analytes efficiently such that the sample preparation steps needed in traditional methods are completely eliminated. The system has detected and confirmed THC in breath out to 4 hours after smoking with breath samples being stored and analyzed up to two days after sample collection. THC in Breath & Blood Data: Study results show that breath levels of THC over time are consistent between subjects and data is demonstrating consistent correlation of levels of THC between breath and whole blood in early time points after smoking. The experimental studies reported here include 10 subjects (6 men, 4 women). Similar to Cannabix’s earlier experiments in Ontario breath samples were collected at baseline (a timepoint just before smoking cannabis) as well as two time points after smoking cannabis, out to 1 hour and 45 minutes. Blood samples were collected at baseline (n=4) and at one timepoint after smoking (between T7 and T30 min, n=10). Breath samples were collected and analyzed using the same hardware and methods as in the previous experimental study in Ontario. Collection was done with the Cannabix BCU, and samples were analyzed using the Cannabix Mass Spectrometer (MS) Breath Sampler coupled to a Thermo TSQ Quantum Ultra MS running in tandem mode. THC and fragment ions were analyzed using Thermo Xcalibur software, and areas under the chromatogram curves (AUC) were determined using the software’s detection feature. Whole blood samples were collected using standardized collection kits by licensed phlebotomists recruited from a local hospital, and were analyzed at a local lab using LC/MS/MS, according to conventional standard operating procedures. The resulting breath data from this study follow the same trend that was seen with experimental data from Ontario study. Breath and whole blood levels of THC were consistent and correlate well within the relatively short time window. Observed breath results further support literature (1) on trends in THC metabolism, similarly to the earlier results. In this study, the storage time between collection and analysis of the breath samples was up to 52 hours (compared to 40 hours in Ontario study). This study further demonstrates that the Cannabix breath sampling and analysis tools function effectively in the field and provide quick and nonintrusive breath sample collection and ease of analysis with no sample preparation needed. In comparison, legacy breath and saliva testing procedures require several sample extraction and preparation steps prior to analysis, and analysis itself can take from 1 - 3 hours per sample. This is expensive and not amenable to high throughput operations. Also, legacy breath and saliva testing procedures have inefficient collection methods and recoveries are still often poor. Blood is currently the standard of measurement for drug determination by law enforcement and toxicologists, and is used as objective evidence of possible impairment in courts of law. Cannabix’s simple and reliable breath collection and analysis method (thus far used in several small preliminary tests) shows very good correlation to blood, which is the standard method to detect and confirm acute cannabis use in the field. The BCU is also being used in concert with the Cannabix FAIMS Detection Unit (FDU), which is being developed as a fully portable system capable of both breath collection and analyses in the field.

Räntetäckningsgrad	n/a
Kontanter	CA$1.26m
Eget kapital	CA$1.57m
Summa skulder	CA$256.13k
Totala tillgångar	CA$1.83m

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/21 08:36
Aktiekurs vid dagens slut	2026/05/21 00:00
Intäkter	2026/01/31
Årlig intjäning	2025/04/30

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Cannabix Technologies Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Viktig information

Nya uppdateringar om finansiell hälsa

Here's Why We're Not Too Worried About Cannabix Technologies' (CSE:BLO) Cash Burn Situation

Cannabix Technologies (CSE:BLO) Is In A Strong Position To Grow Its Business

Here's Why We're Not Too Worried About Cannabix Technologies' (CSE:BLO) Cash Burn Situation

Cannabix Technologies (CSE:BLO) Is In A Strong Position To Grow Its Business

Cannabix Technologies (CSE:BLO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Cannabix Technologies (CSE:BLO) Will Use Its Cash Wisely

Recent updates

New minor risk - Share price stability

Cannabix Technologies Inc Announces Commercial Launch of Marijuana Breath Test

Omega Laboratories Inc and Cannabix Technologies Inc Publish Peer-Reviewed Validation Study Demonstrating Accuracy of Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies Breath Collection Unit

Cannabix Technologies Inc. announced that it has received CAD 0.7 million in funding

Cannabix Technologies Launches New Marijuana Breath Test Product Videos as U.S. Cannabis Reclassification Underscores the Urgent Need for Innovative Public Safety Solutions

Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing

Cannabix Technologies Inc. announced that it expects to receive CAD 2 million in funding

Cannabix Technologies Inc. Announces William (Bill) R. Corl Joins Board of Directors

Cannabix Technologies Receives Notice of Allowance from Cipo for Contactless Breath Analysis Patent Application

Less than half of directors are independent

Cannabix Technologies Inc., Annual General Meeting, Jul 24, 2025

Cannabix Technologies Receives NHTSA Approval for BreathLogix Workplace Series Alcohol Breathalyzer

Cannabix Technologies Inc. Announces the Resignation of Thomas Clarke as Director

New minor risk - Share price stability

Cannabix Technologies Inc. Announces Key Hardware Advancements to Marijuana Breathalyzer Technology

Cannabix Technologies Inc. Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer

Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

Cannabix Technologies Inc. announced that it has received CAD 0.6 million in funding

Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa

New minor risk - Share price stability

Cannabix Technologies Inc., Annual General Meeting, Jun 18, 2024

Here's Why We're Not Too Worried About Cannabix Technologies' (CSE:BLO) Cash Burn Situation

Cannabix Technologies Inc. Appoints Phillip Olla to its Board of Directors

Cannabix Technologies Inc. Announces Resignation of Kulwant Malhi as President and Director

New minor risk - Share price stability

Cannabix Technologies (CSE:BLO) Is In A Strong Position To Grow Its Business

Cannabix Technologies Inc. Files Breath Sample Capture Patent and Detects Delta- 8 THC in Early Testing

Here's Why We're Not Too Worried About Cannabix Technologies' (CSE:BLO) Cash Burn Situation

Cannabix Technologies Inc., Annual General Meeting, Jul 28, 2023

Cannabix Technologies Inc. to Test Contactless Alcohol Breathalyzer in Montana

Cannabix Technologies (CSE:BLO) Is In A Strong Position To Grow Its Business

Less than half of directors are independent

Cannabix Technologies Inc Creates Contactless Alcohol Breath Detection Technology for Workplace and Vehicles

Cannabix Technologies Inc. Announces Participating in A Mid-October Study Date to Test A Supplemental Version of Its Faims Technology for Detection of 9-Tetrahydrocannabino

Cannabix Technologies (CSE:BLO) Is In A Good Position To Deliver On Growth Plans

Cannabix Technologies Inc. Correlates THC in Breath and Blood Using Proprietary Sample Collection and Analysis Hardware in Southern US Study

We're Hopeful That Cannabix Technologies (CSE:BLO) Will Use Its Cash Wisely

Cannabix Technologies Inc., Annual General Meeting, Jul 25, 2022

Less than half of directors are independent

Cannabix Technologies Creates Contactless Alcohol Breath Detection Technology for Vehicles -- Files Provisional Patent

We Think Cannabix Technologies (CSE:BLO) Can Easily Afford To Drive Business Growth

Cannabix Technologies Inc. Develops Version 4.0 of THC Breath Analyzer Device

We Think Cannabix Technologies (CSE:BLO) Can Easily Afford To Drive Business Growth

We're Interested To See How Cannabix Technologies (CSE:BLO) Uses Its Cash Hoard To Grow

Cannabix Technologies Inc. Provides Update on THC Breathalyzer Beta-Testing

CFO, Corporate Secretary & Director exercised options to buy CA$690k worth of stock.

Cannabix Technologies (CSE:BLO) Is In A Strong Position To Grow Its Business

Cannabix Technologies Inc. Develops Version 3.0 of THC Breath Analyzer Device

New 90-day high: CA$1.92

New 90-day high: CA$1.46

Companies Like Cannabix Technologies (CSE:BLO) Can Afford To Invest In Growth

New 90-day high: CA$0.49

New 90-day low: CA$0.40

Cannabix Technologies Inc. Achieves New Plateau with its FAIMS Marijuana Breathalyzer Technology

Analys av finansiell ställning

Skuld till eget kapital Historik och analys

Balansräkning

Analys av kontantbanan

Upptäck friska företag

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker